NeoGenomics, Inc. Deferred Federal Income Tax Expense (Benefit)
NeoGenomics, Inc. (NEO) reported Deferred Federal Income Tax Expense (Benefit) of $112.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-17
- NeoGenomics, Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $112.00K.
- NeoGenomics, Inc. deferred federal income tax expense (benefit) for fiscal 2024 was -$340.00K.
- NeoGenomics, Inc. deferred federal income tax expense (benefit) for fiscal 2023 was -$373.00K, a 160.75% decline from fiscal 2022.
- NeoGenomics, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was $614.00K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $112.00K 10-K · filed 2026-02-17 | |
| 2024-12-31 | -$340.00K 10-K · filed 2026-02-17 | |
| 2023-12-31 | -$373.00K 10-K · filed 2026-02-17 | |
| 2022-12-31 | $614.00K 10-K · filed 2025-02-18 | |
| 2021-12-31 | -$575.00K 10-K · filed 2024-02-20 | |
| 2020-12-31 | -$12.86M 10-K · filed 2023-02-24 | |
| 2019-12-31 | -$3.41M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $1.07M 10-K · filed 2021-02-25 | |
| 2017-12-31 | -$2.36M 10-K · filed 2020-02-28 | -$2.74M 10-K · filed 2018-03-13 |
| 2016-12-31 | -$1.45M 10-K · filed 2019-02-26 | |
| 2015-12-31 | -$1.87M 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |